| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.003 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | 0.096 | 0.003 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | 0.15 | 0.003 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.003 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | -0.092 | 0.004 |
| mRNA | temsirolimus | CTRPv2 | pan-cancer | AAC | -0.14 | 0.004 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.004 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.092 | 0.004 |
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.004 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | -0.089 | 0.004 |